Vaniqa, a hair growth retardant, is indicated to reduce unwanted facial hair in women. It is thought to work by irreversibly inhibiting skin ornithine decarboxylase (ODC) activity, an enzyme needed for the synthesis of polyamines. By inhibiting ODC, cell division and synthesis are blocked thus affecting the rate of hair growth.
The product is anticipated to become available again in August 2018. It is supplied in 30g and 60g packages.
For more information call (800) 678-1605 or visit FDA.gov.